MHRA Authorises Eli Lilly’s Orforglipron as First Oral GLP-1 Tablet in Europe

The orforglipron MHRA approval represents the first European authorisation of this once-daily oral glucagon-like peptide-1 receptor agonist for weight reduction and maintenance in adults with specified body mass index thresholds, alongside lifestyle interventions, and for improving glycaemic control in adults with inadequately managed type 2 diabetes. This decision followed a rigorous evaluation confirming that benefits outweigh risks when the medicine is used under appropriate medical supervision, with ongoing pharmacovigilance planned to track real-world performance.

Orforglipron MHRA Approval Sets European Precedent

The orforglipron MHRA approval was granted on 10 August 2026 after assessment of safety data, manufacturing quality and clinical evidence submitted by the sponsor. Dose escalation begins at 0.8 mg and increases monthly up to a maximum of 17.2 mg to optimise tolerability while achieving therapeutic effect. Unlike some injectable alternatives, the tablet can be taken without regard to meals or timing, which may improve convenience for patients managing chronic conditions.

Mechanism and Clinical Performance

Orforglipron mimics endogenous GLP-1 signalling to reduce appetite through central nervous system pathways and to limit post-meal glucose spikes in type 2 diabetes. Gastrointestinal adverse events such as nausea, constipation, diarrhoea, vomiting, dyspepsia and abdominal discomfort were the most frequently reported effects during clinical evaluation. Although regulatory clearance has been secured, immediate National Health Service availability depends on separate health technology assessment processes that determine funding and access.

Ad

Market Access and Health Economics Considerations

Health economics evaluations will need to factor in the oral formulation’s ease of use and the structured titration schedule when projecting adherence compared with injectable GLP-1 receptor agonists. Reimbursement decisions by the National Institute for Health and Care Excellence will ultimately shape the size of the eligible population beyond the regulatory label. Payer discussions must also address the prescription-only status and warnings against unregulated sourcing to protect patient safety. Further details are available in the official UK government announcement. Long-term monitoring will continue to assess durability of weight and glycaemic outcomes in routine clinical practice across diverse patient groups.